Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer's disease

Biological Psychiatry

Volumn 77, Issue 8, 2015, Pages 704-710

  Ortner, Marion ^a   Kurz, Alexander ^a   Alexopoulos, Panagiotis ^a   Auer, Florian ^a   Diehl Schmid, Janine ^a   Drzezga, Alexander ^c   Förster, Stefan ^a   Förstl, Hans ^a   Perneczky, Robert ^a,d,e   Sorg, Christian ^a   Yousefi, Behrooz H ^b   Grimmer, Timo ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

Author keywords

AD; Age at onset; Alzheimer's disease; Amyloid load; Metabolic deficit; Small vessel disease

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B; BENZOTHIAZOLE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE NEUROPSYCHOLOGICAL ASSESSMENT BATTERY; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DEMENTIA; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; GENOTYPE; GROUPS BY AGE; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONSET AGE; PATHOPHYSIOLOGY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; BRAIN; COMPLICATION; GENETICS; METABOLIC DISEASES; METABOLISM; PATHOLOGY; SCINTISCANNING; VASCULAR DISEASES; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; APOLIPOPROTEINS E; BENZOTHIAZOLES; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; VASCULAR DISEASES;

EID: 84933277795     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.01.019     Document Type: Conference Paper

References (44)

1. Alzheimer A (1906): Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt 1129-1136.
2. Alzheimer A (1907): Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Pschisch-Gerichtliche Medizin 146-148.
3. Kraepelin E (1910): Psychiatrie: Ein Lehrbuch für Studierende und Ärzte. II. Band Klinische Psychiatrie. 1. Teil, 8th ed. Leipzig: Barth Verlag.
4. Katzman R (1976): The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol 33:217-218.
5. Tagliavini F, Pilleri G (1983): Neuronal counts in basal nucleus of Meynert in Alzheimer disease and in simple senile dementia. Lancet 1: 469-470.
6. Bigio EH, Hynan LS, Sontag E, Satumtira S, White CL (2002): Synapse loss is greater in presenile than senile onset Alzheimer disease: Implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 28:218-227.
7. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD (1992): Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 13:93-98.
8. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. (2005): Glucose metabolism in early onset versus late onset Alzheimer's disease: An SPM analysis of 120 patients. Brain 128:1790-1801.
9. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. (2010): Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 133: 512-528.
10. Choo IH, Lee DY, Kim JW, Seo EH, Lee DS, Kim YK, et al. (2011): Relationship of amyloid-beta burden with age-at-onset in Alzheimer disease. Am J Geriatr Psychiatry 19:627-634.
11. Pellerin L, Magistretti PJ (1994): Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 91:10625-10629.
12. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. (2004): Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
13. Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, et al. (1996): Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII. Neurology 46:136-141.
14. Smits LL, Pijnenburg YA, Koedam EL, van der Vlies AE, Reuling IE, Koene T, et al. (2012): Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. J Alzheimers Dis 30:101-108.
15. Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, et al. (2012): Amyloid burden and metabolic function in early-onset Alzheimer's disease: Parietal lobe involvement. Brain 135:2115-2125.
16. Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, et al. (2009): Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 30:1902-1909.
17. Salmon E, Lespagnard S, Marique P, Peeters F, Herholz K, Perani D, et al. (2005): Cerebral metabolic correlates of four dementia scales in Alzheimer's disease. J Neurol 252:283-290.
18. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A (2006): Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 14:139-144.
19. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, et al. (2009): Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487-1494.
20. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. (2005): Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 64:102-107.
21. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P (2009): Epidemiological pathology of dementia: Attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6:e1000180.
22. Chowdhury MH, Nagai A, Bokura H, Nakamura E, Kobayashi S, Yamaguchi S (2011): Age-related changes in white matter lesions, hippocampal atrophy, and cerebral microbleeds in healthy subjects without major cerebrovascular risk factors. J Stroke Cerebrovasc Dis 20:302-309.
23. Jellinger KA (2010): Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. Neurodegener Dis 7:112-115.
24. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997): Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813-817.
25. Pantoni L (2010): Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689-701.
26. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al. (2004): Cerebral white matter lesions and the risk of dementia. Arch Neurol 61:1531-1534.
27. Scheltens P, Barkhof F, Valk J, Algra PR, van der Hoop RG, Nauta J, et al. (1992): White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain 115(pt 3):735-748.
28. Grimmer T, Faust M, Auer F, Alexopoulos P, Forstl H, Henriksen G, et al. (2012): White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 33:2766-2773.
29. Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
30. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. (1989): The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:1159-1165.
31. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, et al. (1997): Clinical dementia rating training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study experience. Neurology 48:1508-1510.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
33. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. (2000): FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41:1920-1928.
34. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007): What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69:871-877.
35. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. (2011): The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269.
36. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. (1993): Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260.
37. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U (1997): Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 43:1657-1659.
38. Grimmer T, Diehl J, Drzezga A, Forstl H, Kurz A (2004): Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: A prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord 18:32-36.
39. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. (2005): Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46:1959-1972.
40. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al. (1993): A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7-12.
41. Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H, et al. (2010): Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry 68:879-884.
42. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289.
43. Loening AM, Gambhir SS (2003): AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2:131-137.
44. Friston KJ (1995): II. Statistical parametric mapping: Ontology and current issues. J Cereb Blood Flow Metab 15:361-370.